---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-078152"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:05:47.179713+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nkarta initiates Ntrust-1 in lupus nephritis, IND cleared for 3 more autoimmune indications

## Summary
- First patient in screening for Ntrust-1, a trial of NKX019 in refractory lupus nephritis.
- FDA cleared IND for NKX019 in systemic sclerosis, myositis, and ANCA-associated vasculitis (Ntrust-2).
- Both trials are dose-escalation, open-label, multi-center, designed for up to 12 patients each.
- Clinical data from Ntrust-1 and Ntrust-2 expected in 2025.

## SEC filing metadata
- accession: 0000950170-24-078152
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017024078152/0000950170-24-078152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017024078152/nktx-20240627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-078152
- JSON: https://secwatch.observer/filing/0000950170-24-078152.json
- Plain text: https://secwatch.observer/filing/0000950170-24-078152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.